Drug Trial Radar · NCT07341282
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Jun 17, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- McMaster UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Weston Family Foundation
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.
Conditions
- Ulcerative Colitis (UC)
- Primary Sclerosing Cholangitis (PSC)
Interventions
Placebo (blinded)Drug
Identical placebo capsule administered orally twice daily for 4 weeks.
Vancomycin (blinded)Drug
Vancomycin 250 mg administered orally twice daily for 4 weeks.
Vancomycin (open-label extension)Drug
Vancomycin 250 mg administered orally twice daily for 4 weeks (optional extension offered to both arms).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recruitment rateTime frame: 12 months
- Retention rateTime frame: 12 months
- Treatment adherenceTime frame: 12 months
- Protocol compliance with study proceduresTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
McMaster Children's Hospital - Digestive Diseases Clinic
Hamilton, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.